Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia

Avi Leader*, Anna Gurevich-Shapiro, Galia Spectre

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)

Abstract

Antithrombotic therapy (anticoagulation or antiplatelet therapy) is frequently prescribed in cancer patients for prior or new indications such as venous thromboembolism, secondary prevention of arterial thrombosis or atrial fibrillation. Therefore, it is not uncommon for thrombocytopenic cancer patients to have an indication for antithrombotic therapy. Thrombocytopenia does not reduce the risk of recurrent thrombosis. The bleeding risk with anticoagulation appears to increase when platelets are

Original languageEnglish
Pages (from-to)S68-S73
Number of pages6
JournalThrombosis Research
Volume191
DOIs
Publication statusPublished - Jul 2020
Event10th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) - Bergamo, Italy
Duration: 17 Apr 202019 Apr 2020

Keywords

  • Anticoagulation
  • Antiplatelet therapy
  • Atrial fibrillation
  • Cancer
  • Venous thromboembolism
  • Thrombocytopenia
  • ELEVATION MYOCARDIAL-INFARCTION
  • ACUTE CORONARY SYNDROME
  • PROPHYLACTIC PLATELET TRANSFUSIONS
  • RECURRENT VENOUS THROMBOEMBOLISM
  • HEMATOLOGIC MALIGNANCY PATIENTS
  • STEM-CELL-TRANSPLANTATION
  • MOLECULAR-WEIGHT HEPARIN
  • MARROW-TRANSPLANTATION
  • VENOOCCLUSIVE DISEASE
  • ATRIAL-FIBRILLATION

Cite this